PATENT CLAIM ANALYSIS

Application Number: 15750479
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2019-01
Patent Classification: ["514", "050000"]

Abstract:
The present invention relates to salts of anthelmintic compounds with a benzimidazolic structure, such as albendazole (ABZ), fenbendazole (FBZ), triclabendazole (TRBZ), or sulphoxides thereof, flubendazole (FLZ), mebendazole (MBZ), oxibendazole (OBZ), thiabendazole (TBZ), cambendazole (CBZ), parbendazole (PBZ), nocodazole (NCZ), the use thereof and a process for preparation thereof.

Claim (Index 14):
Combination according to  claim 13 , for use according to  claim 13 , wherein said at least one further antitumour drug is selected in the group consisting of taxanes such as paclitaxel, docetaxel and cabazitaxel, camptothecins such as, for example, irinotecan and topotecan,  Vinca  alkaloids, platinum complexes such as oxaliplatin, cisplatin and carboplatin, temozolomide, gemcitabin, capecitabine and bevacizumab.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 88.0
- Lexical Diversity: 1.66667
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15111711', '14440140', '12801853', '10485530', '14085632']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7782864553134806
- 35 USC 102 Novelty (BERT): 0.4859199709022962
- Combined Prediction Score: 0.7490498068723622
- Mean Citation Score: 170.215304
- Max Citation Score: 183.41043
- Similarity Product: 126.55913240036128

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test